Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 33.3%GRADE not reported 4 · 66.7%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Antimicrobial lozenge vs Placebo · Xerostomia
  Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  Up to and including 3 months postRT
  RR 1.16 [0.97, 1.40]
  1 study · 133 participants
  GRADE not reported
Direct match · question page
- Antimicrobial lozenge vs Placebo · Salivary flow rate
  Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No data on salivary flow rates were reported.
  0 studies
  No studies found
Direct match · question page
- Antimicrobial lozenge vs Placebo · Quality of life and other oral related symptoms
  Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  Over 6 months
  Insufficient evidence of a difference for global quality of life, mouth pain RR 0.94 (95% CI 0.66 to 1.33), sore/burning mouth RR 0.95 (95% CI 0.68 to 1.35), throat pain RR 0.79 (95% CI 0.56 to 1.12) (Duncan 2005)
  1 study
  GRADE not reported
Direct match · question page
- Antimicrobial lozenge vs Placebo · Side effects (other: dryness in mouth, diarrhoea, constipation)
  Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  Over 6 months
  Insufficient evidence of a difference: dryness in mouth RR 1.18 (95% CI 0.97 to 1.42), diarrhoea RR 1.97 (95% CI 0.51 to 7.54), constipation RR 0.91 (95% CI 0.59 to 1.42) (Duncan 2005)
  1 study
  GRADE not reported
Related · question page
- Antimicrobial lozenge vs Placebo · Nausea (adverse effect)
  Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  Over 6 months
  RR 1.90 [1.10, 3.28]
  1 study · 131 participants
  GRADE not reported

Antimicrobial lozenge vs placebo

Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Antimicrobial lozenge showed no clear difference in xerostomia compared with placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Up to and including 3 months postRT
RR 1.16 [0.97, 1.40]
1 study · 133 participants
GRADE not reported

Antimicrobial lozenge vs placebo

Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No survival data were reported.
0 studies
No studies found

Antimicrobial lozenge vs placebo

Nausea · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Antimicrobial lozenge led to higher nausea (adverse effect) compared with placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Over 6 months
RR 1.90 [1.10, 3.28]
1 study · 131 participants
GRADE not reported

Antimicrobial lozenge vs placebo

Quality of life and other oral related symptoms · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Over 6 months
Insufficient evidence of a difference for global quality of life, mouth pain RR 0.94 (95% CI 0.66 to 1.33), sore/burning mouth RR 0.95 (95% CI 0.68 to 1.35), throat pain RR 0.79 (95% CI 0.56 to 1.12) (Duncan 2005)
1 study
GRADE not reported

Antimicrobial lozenge vs placebo

Side effects (other: dryness in mouth, diarrhoea, constipation) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Over 6 months
Insufficient evidence of a difference: dryness in mouth RR 1.18 (95% CI 0.97 to 1.42), diarrhoea RR 1.97 (95% CI 0.51 to 7.54), constipation RR 0.91 (95% CI 0.59 to 1.42) (Duncan 2005)
1 study
GRADE not reported

Antimicrobial lozenge vs placebo

Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No data on salivary flow rates were reported.
0 studies
No studies found